Mark J. Tebbe, Ph.D.
Mark has 27 years of experience in drug discovery and development and is a co-inventor of Incivek (Telaprevir), an HCV protease inhibitor as well as numerous other candidates across multiple disease areas. Mark is a serial entrepreneur and was most recently the co-founder and Chief Technology Officer of Quench Bio working on therapies targeting the chronic, aberrant activation of the innate immune system. Prior to that, he was Head of Drug Discovery at Quartet Medicine working on peripheral neuropathic pain. His first biotech role was as VP of Medicinal and Computational Chemistry at Forma Therapeutics where he focused on small molecule cancer therapeutics. Prior to joining biotech, Mark held positions of increasing responsibility during his 16-year career at Eli Lilly including head of chemistry in Hamburg, Germany and Research Triangle Park, North Carolina as well as Global Head of Operations for the discovery chemistry group. He obtained his Ph.D. in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame.